Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Treating enfortumab vedotin related AEs in urothelial carcinoma

Rohit Jain • 14 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Antibodies Enfortumab vedotin

Rohit Jain, MD, MPH, Weill Cornell Medicine, New York, NY, comments on the main toxicities associated with enfortumab vedotin (EV) with pembrolizumab in patients with urothelial carcinoma. The main adverse events (AEs) of EV include a skin rash, which can be managed with barrier creams and corticosteroids, and neuropathy, which can be addressed with supportive care and medications. Additionally, hyperglycemia is a significant concern, requiring close monitoring. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rohit Jain

Evaluating the current treatment landscape of urothelial carcinoma
0:35
Evaluating the current treatment landscape of urothelial carcinoma
Rohit Jain • 14 Feb 2025
ETCTN 10483: erdafitinib and EV in FGFR3/2-altered urothelial cancer
2:49
ETCTN 10483: erdafitinib and EV in FGFR3/2-altered urothelial cancer
Rohit Jain • 14 Feb 2025
Sequencing ADCs and finding novel biomarkers for urothelial carcinoma
0:46
Sequencing ADCs and finding novel biomarkers for urothelial carcinoma
Rohit Jain • 26 Jan 2024
Ipilimumab plus nivolumab with sacituzumab govitecan in mUC
0:57
Ipilimumab plus nivolumab with sacituzumab govitecan in mUC
Rohit Jain • 26 Jan 2024

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals